ICLR Stock Overview
A clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for ICLR from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
ICON Public Limited Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$207.51 |
| 52 Week High | US$347.72 |
| 52 Week Low | US$183.38 |
| Beta | 1.2 |
| 1 Month Change | -3.15% |
| 3 Month Change | -29.97% |
| 1 Year Change | -26.05% |
| 3 Year Change | -32.61% |
| 5 Year Change | 20.73% |
| Change since IPO | 3,162.99% |
Recent News & Updates
ICON: A High Probability Of Success In The Uncertain R&D Process
Dec 13At US$219, Is ICON Public Limited Company (NASDAQ:ICLR) Worth Looking At Closely?
Dec 10
ICON: Disappointing Change In Trajectory (Rating Downgrade)
Nov 29With A 25% Price Drop For ICON Public Limited Company (NASDAQ:ICLR) You'll Still Get What You Pay For
Nov 02Recent updates
ICON: A High Probability Of Success In The Uncertain R&D Process
Dec 13At US$219, Is ICON Public Limited Company (NASDAQ:ICLR) Worth Looking At Closely?
Dec 10ICON: Disappointing Change In Trajectory (Rating Downgrade)
Nov 29With A 25% Price Drop For ICON Public Limited Company (NASDAQ:ICLR) You'll Still Get What You Pay For
Nov 02Here's Why ICON (NASDAQ:ICLR) Has Caught The Eye Of Investors
Sep 25Should You Think About Buying ICON Public Limited Company (NASDAQ:ICLR) Now?
Sep 09We Think ICON (NASDAQ:ICLR) Can Stay On Top Of Its Debt
Aug 25An Intrinsic Calculation For ICON Public Limited Company (NASDAQ:ICLR) Suggests It's 28% Undervalued
Aug 10ICON: Deleveraging Complete, Now See 18% CAGR In Valuation To FY'26E (Rating Upgrade)
Jul 13Earnings Tell The Story For ICON Public Limited Company (NASDAQ:ICLR)
Jun 14Here's Why We Think ICON (NASDAQ:ICLR) Is Well Worth Watching
May 30ICON (NASDAQ:ICLR) Has A Pretty Healthy Balance Sheet
May 14ICON Public Limited Company Just Recorded A 8.9% EPS Beat: Here's What Analysts Are Forecasting Next
Apr 28What Does ICON Public Limited Company's (NASDAQ:ICLR) Share Price Indicate?
Apr 21ICON Public Limited Company's (NASDAQ:ICLR) Intrinsic Value Is Potentially 33% Above Its Share Price
Apr 05ICON Public Limited Company (NASDAQ:ICLR) Looks Just Right With A 27% Price Jump
Mar 05With EPS Growth And More, ICON (NASDAQ:ICLR) Makes An Interesting Case
Feb 07ICON: Will The Huge Acquisition Of PRA Continue To Create Synergies?
Feb 01These 4 Measures Indicate That ICON (NASDAQ:ICLR) Is Using Debt Reasonably Well
Jan 23Is It Too Late To Consider Buying ICON Public Limited Company (NASDAQ:ICLR)?
Jan 08What You Can Learn From ICON Public Limited Company's (NASDAQ:ICLR) P/E
Dec 24Icon selected by BARDA to conduct anthrax vaccine clinical trial
Oct 06Shareholder Returns
| ICLR | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -0.3% | -2.1% | -2.4% |
| 1Y | -26.0% | -5.5% | 23.4% |
Return vs Industry: ICLR underperformed the US Life Sciences industry which returned -5.5% over the past year.
Return vs Market: ICLR underperformed the US Market which returned 23.3% over the past year.
Price Volatility
| ICLR volatility | |
|---|---|
| ICLR Average Weekly Movement | 7.4% |
| Life Sciences Industry Average Movement | 9.2% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ICLR has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ICLR's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 42,250 | Steve Cutler | www.iconplc.com |
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization.
ICON Public Limited Company Fundamentals Summary
| ICLR fundamental statistics | |
|---|---|
| Market cap | US$17.13b |
| Earnings (TTM) | US$747.89m |
| Revenue (TTM) | US$8.31b |
22.9x
P/E Ratio2.1x
P/S RatioIs ICLR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ICLR income statement (TTM) | |
|---|---|
| Revenue | US$8.31b |
| Cost of Revenue | US$5.85b |
| Gross Profit | US$2.46b |
| Other Expenses | US$1.71b |
| Earnings | US$747.89m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 9.06 |
| Gross Margin | 29.64% |
| Net Profit Margin | 9.00% |
| Debt/Equity Ratio | 35.1% |
How did ICLR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 02:00 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ICON Public Limited Company is covered by 45 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Armelle Moulin | AlphaValue |
| Gregory Bolan | Avondale Partners |
| Eric Coldwell | Baird |